FADS1/2 variants rs174547 and rs1535 reduce desaturase activity and lower AA and EPA levels.

The conversion of essential fatty acids into long-chain polyunsaturated fatty acids (LC-PUFAs) is heavily dictated by genetic variation within the FADS1 and FADS2 gene cluster. Variants such as rs174547 and rs1535 are confirmed genetic determinants that modulate the activity of delta-5 and delta-6 desaturase enzymes, which are the rate-limiting steps in these metabolic pathways.

Clinical evidence and LC-PUFA balance

Clinical studies consistently demonstrate that carriers of specific minor alleles (e.g., the C allele of rs174547) exhibit significantly altered LC-PUFA profiles.

• Reduced Conversion: Research indicates a 15–50% reduction in the conversion of dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA) in individuals with low-activity variants.
• AA and EPA Levels: These variants lead to lower plasma and erythrocyte levels of both AA (n-6) and eicosapentaenoic acid (EPA, n-3). While dietary intake can mask some effects, the genetic influence remains a primary driver of the endogenous pool.
• Inflammatory Ratios: The ratio of AA to EPA is a key marker of systemic inflammatory potential. High-activity genotypes often correlate with a higher AA:EPA ratio, particularly when dietary n-3 intake is insufficient, potentially skewing the body toward a pro-inflammatory state.

Mechanistic explanations

The FADS gene cluster on chromosome 11 acts as a powerful expression quantitative trait locus (eQTL).

• Transcriptional Downregulation: Variants like rs174547 are part of a haplotype block that influences FADS1 and FADS2 mRNA expression. Minor alleles are linked to reduced mRNA levels in critical metabolic tissues such as the liver and adipose tissue.
• Enzymatic Bottleneck: Reduced mRNA expression leads to lower availability of delta-5 desaturase (D5D) and delta-6 desaturase (D6D). This creates a metabolic bottleneck, slowing the desaturation of short-chain precursors (like ALA and LA) into their long-chain, bioactive counterparts.

Bottom line

Genetic variants rs174547 and rs1535 significantly reduce desaturase activity, leading to lower levels of AA and EPA and altering the AA:EPA inflammatory ratio. For individuals with these variants, tailoring dietary intake of pre-formed LC-PUFAs (such as through fish or algae oil) may be necessary to bypass this genetic metabolic bottleneck.